MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406577 | Name: P005091
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

P005091 is a potent and selective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 μ M). P005091 induces elevated p53 and apoptosis in cancer cell lines and displays antiangiogenic activity in vivo . The deubiquitylating enzyme USP7 (HAUSP) sits at a critical node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators. Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention.

Chemical Structure

P005091
P005091
CAS#882257-11-6

Theoretical Analysis

MedKoo Cat#: 406577

Name: P005091

CAS#: 882257-11-6

Chemical Formula: C12H7Cl2NO3S2

Exact Mass: 346.9244

Molecular Weight: 348.21

Elemental Analysis: C, 41.39; H, 2.03; Cl, 20.36; N, 4.02; O, 13.78; S, 18.42

Price and Availability

Size Price Availability Quantity
10mg USD 310.00
25mg USD 550.00
50mg USD 750.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
P005091; P-005091; P 005091; P5091; P-5091; P 5091.
IUPAC/Chemical Name
1-(5-((2,3-dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone
InChi Key
LKZLGMAAKNEGCH-UHFFFAOYSA-N
InChi Code
1-(5-((2,3-dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3
SMILES Code
CC(C1=CC([N+]([O-])=O)=C(SC2=CC=CC(Cl)=C2Cl)S1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C8Y01M09
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC50 of 4.2 μM.
In vitro activity:
As shown in the results of Fig. 2A, treatment with different concentrations of P5091 for different times resulted in a significant decrease in the viability of both cell lines. The IC50 of SHG-140 and T98G cells were 1.2 µM and 1.59 µM, respectively, when treated with P5091 for 48 h. Application of P5091 caused a concentration-dependent increase in early-, late-stage apoptosis and total apoptosis in GBM cells. Reference: Cancer Cell Int. 2021 Sep 23;21(1):508. https://pubmed.ncbi.nlm.nih.gov/34556124/
In vivo activity:
Treatment of MM.1S tumor-bearing mice with intravenous (IV) injection of P5091 inhibits MM tumor growth and prolongs survival of these mice (Fig 6A and 6B). Examination of harvested tumors showed that P5091 inhibited USP7 activity, decreased HDM2, and increased p21 levels relative to tumors from control mice (Fig 6C). P5091 decreases proliferation in harvested tumors, as assessed by BrdU and Ki67 staining (Fig 6D, and Fig S5A). P5091 increases the number of cleaved-caspase-3-, and TUNEL-positive apoptotic tumor cells versus vehicle treatment (Fig 6E, and Fig S5B). Reference: Cancer Cell. 2012 Sep 11;22(3):345-58. https://pubmed.ncbi.nlm.nih.gov/22975377/
Solvent mg/mL mM comments
Solubility
DMF 3.0 8.62
DMF:PBS (pH 7.2) (1:2) 0.3 0.86
DMSO 17.1 49.01
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 348.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, Bonaldi T, Confalonieri S, Pisati F, Giardina G, Bertalot G, Bossi D, Lanfrancone L. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022 Sep 20;40(12):111396. doi: 10.1016/j.celrep.2022.111396. PMID: 36130505. 2. Pan T, Li X, Li Y, Tao Z, Yao H, Wu Y, Chen G, Zhang K, Zhou Y, Huang Y. USP7 inhibition induces apoptosis in glioblastoma by enhancing ubiquitination of ARF4. Cancer Cell Int. 2021 Sep 23;21(1):508. doi: 10.1186/s12935-021-02208-z. PMID: 34556124; PMCID: PMC8461901. 3. Ye M, He J, Zhang J, Liu B, Liu X, Xie L, Wei M, Dong R, Li K, Ma D, Dong K. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway. Cancer Biomark. 2021;31(2):107-117. doi: 10.3233/CBM-200052. PMID: 33780361. 4. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11;22(3):345-58. doi: 10.1016/j.ccr.2012.08.007. PMID: 22975377; PMCID: PMC3478134.
In vitro protocol:
1. Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A, Bonaldi T, Confalonieri S, Pisati F, Giardina G, Bertalot G, Bossi D, Lanfrancone L. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022 Sep 20;40(12):111396. doi: 10.1016/j.celrep.2022.111396. PMID: 36130505. 2. Pan T, Li X, Li Y, Tao Z, Yao H, Wu Y, Chen G, Zhang K, Zhou Y, Huang Y. USP7 inhibition induces apoptosis in glioblastoma by enhancing ubiquitination of ARF4. Cancer Cell Int. 2021 Sep 23;21(1):508. doi: 10.1186/s12935-021-02208-z. PMID: 34556124; PMCID: PMC8461901.
In vivo protocol:
1. Ye M, He J, Zhang J, Liu B, Liu X, Xie L, Wei M, Dong R, Li K, Ma D, Dong K. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway. Cancer Biomark. 2021;31(2):107-117. doi: 10.3233/CBM-200052. PMID: 33780361. 2. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11;22(3):345-58. doi: 10.1016/j.ccr.2012.08.007. PMID: 22975377; PMCID: PMC3478134.
 Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011 Jun;60(1-2):61-8. doi: 10.1007/s12013-011-9185-5. PMID: 21468693. Xia, J., He, Y., Meng, B., Chen, S., Zhang, J., Wu, X., ... & Zhou, W. (2020). NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma. Molecular oncology, 14(4), 763-778.